Enzychem Lifesciences Corp (KOSDAQ:183490) CEO Ki Young Sohn sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The South Korea and New Jersey-based biopharma company's lead compound is an immune resolution accelerator that is derived from deer antlers, with the potential to be used for a variety of indications.
Enzychem Lifesciences advancing its therapy derived from deer antlers
Enzychem Lifesciences Corp (KOSDAQ:183490) CEO Ki Young Sohn sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The South Korea and New Jersey-based biopharma company's lead compound is an immune resolution accelerator that is derived from deer antlers, with the potential to be used for a variety of indications.
0 Comments